Bio-Rad to commercialize VISIA Imaging's immunofluorescence slide technology

VISIA Imaging is proud to say that Bio-Rad Laboratories has entered into an agreement that gives it commercialization rights to VISIA Imaging's second-generation immunofluorescence slide processing and reading platform for the evaluation of autoimmune diseases.

VISIA's second-generation system integrates automated slide processing with reading of immunofluorescence slides, and Bio-Rad noted that the platform will be used to automatically process slides, capture images, and aid in the interpretation of immunofluorescence results.

"We are excited about the opportunity to partner with VISIA Imaging", said John Hertia, Bio-Rad Executive Vice President and President, Clinical Diagnostics. "The platform offers a standardized and automated workflow that is needed by laboratories to handle their ever increasing IFA workloads."

"We are delighted to work with Bio-Rad Laboratories for the commercialization of this platform into new global markets", said Alessandro Foggi, CEO of VISIA Imaging. "As the worldwide prevalence of autoimmune disease continues to grow, laboratories will benefit from this automated digital platform that includes slide processing, image acquisition, analysis, and archiving."

For more information, please refer to the following link at Bio-Rad website.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries.

Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,350 people worldwide and had revenues exceeding $2 billion in 2016.

For more information, please visit